Developer docs
API playgroundTry for free, no card

Search company profiles

Astromech

Full company profile

uuid0000k7s

Namestring
Astromech
Legal namestring
Astromech AI Corp.
Websiteurl
astromech.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Astromech is a private AI company founded in 2025 and headquartered in Austin, Texas (Delaware-incorporated as Astromech AI Corp.), operating as a wholly-owned subsidiary of Colossal Biosciences. The company is building the "Large Life Model" — an autonomous biological intelligence system purpose-built to decode the regulatory and evolutionary logic of biology, in contrast to general-purpose large language models. The architecture is designed to operate across multi-species inputs and transcriptomic data, incorporating ancestral reconstruction to form a continuously updating biological intelligence layer that supports therapeutic development, trait optimization, programmable biology, and synthetic design. Target users are life sciences and biotech researchers working on understanding and shaping biological systems, with pain points centered on the lack of AI systems capable of multi-species analysis, ancestral reconstruction, and causal evolutionary reasoning.

The technical platform comprises five specialized components: the Pilot's Heuristic Processor (attention-based deep learner for multi-species transcriptomes), the Astrogation Buffer (Bayesian Ancestral Reconstruction for evolutionary trajectories), the Multi-socket Docking Bay (graph-based pangenome capturing population-scale structural variants), Tool-Appendage Calibration (Profile HMM alignment across divergent lineages), and the Droid Grid Network (multi-omics integrator in development). The system is described as an "AI Co-Pilot Through Evolutionary Frontiers" and is being designed to execute rather than merely assist. Leadership includes CEO Ben Lamm, Advisor George Church, and CLO Brian Beard, drawing on Colossal's de-extinction research programs (woolly mammoth, dire wolf, dodo, blue buck) as biological context.

Astromech operates in stealth with no publicly disclosed pricing, no commercial product storefront, and no named customer logos. Approximately $40 million has been raised through a 2025 $30M seed round and a March 2026 SEC Form D filing for $10,499,999, reaching a $2 billion+ unicorn valuation within nine months of founding. Go-to-market is relationship-driven, targeting research institutions and biotech companies through early-access newsletter signup and direct outreach, with an extensive job directory signaling aggressive technical talent acquisition.

Short descriptiontext

Astromech, a Colossal Biosciences subsidiary, develops the Large Life Model — a proprietary AI system purpose-built to decode biological regulation and evolutionary logic across multi-species data for life sciences and biotech researchers.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biological AI systems, genomic AI platform, synthetic biology tools, multi-omics analysis, evolutionary reconstruction AI
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
Product category
Bioinformatics AI Platform
No data
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Large Life Model
Description

A developing AI system purpose-built to decode the regulatory and evolutionary logic of biology. It operates across multi-species inputs and transcriptomic data, incorporating ancestral reconstruction to form a continuously updating biological intelligence layer.

astromech.com
Core offering1 text field

Astromech develops an AI platform called the Large Life Model, purpose-built to decode the regulatory and evolutionary logic of biology. The system operates across multi-species inputs and transcriptomic data, incorporating ancestral reconstruction to form a continuously updating biological intelligence layer. It supports therapeutic development, trait optimization, programmable biology, genomic reasoning, synthesis design, and evolutionary reconstruction for life sciences and biotech research organizations.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Astromech is an AI company founded as a subsidiary of Colossal Biosciences, developing a unified biological intelligence platform centered on the Large Life Model. This core AI system is complemented by five specialized technical components: the Pilot's Heuristic Processor (attention-based deep learning across transcriptomes), Astrogation Buffer (Bayesian ancestral reconstruction), Multi-socket Docking Bay (graph-based pangenome analysis), Tool-Appendage Calibration (Profile HMM alignment), and the Droid Grid Network (multi-omics integration). The platform is designed as an autonomous biological intelligence system that enables researchers to navigate, analyze, and predict biological processes at scale.

Product and service1 record
1Large Life Model
CategoryCore AI Platform
Description

An AI system purpose-built to decode the regulatory and evolutionary logic of biology. Operates across multi-species inputs and transcriptomic data with ancestral reconstruction capabilities, enabling high-resolution insights for therapeutic development, trait optimization, and programmable biology. Targeted at life sciences researchers and biotech organizations.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Astromech was launched as an AI-focused subsidiary of Colossal Biosciences, a Texas-based biotech company founded by Ben Lamm. Colossal's work on de-extinction (woolly mammoth, dire wolf, dodo, Blue Buck) provides the biological research context for Astromech's Large Life Model development. The companies share founding leadership including Ben Lamm as CEO and George Church as Advisor.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery platform combining machine learning with high-throughput biology. Comparable in target customer (pharma/biotech research) and value proposition (predictive biology from large-scale data).

TypeBroad incumbent
Description

Cloud-based R&D platform for life sciences (LIMS/ELN) used across pharma and biotech. Comparable as adjacent life-science informatics infrastructure serving similar research customers.

TypeBroad incumbent
Description

Large, publicly traded synthetic biology platform serving ag, industrial, and pharma customers. Comparable in synthetic biology positioning and horizontal life-science platform scope, though much broader and less AI-native.

TypeDirect peer
Description

AI platform for protein engineering and design, serving biotech customers with generative biology tooling. Comparable in horizontal life-science R&D application and AI-driven design value proposition.

TypeDirect peer
Description

Publicly traded AI drug discovery company using high-dimensional biology and foundation models. Direct competitor in the AI-for-therapeutic-development category, with a mature pipeline and pharma partnerships Astromech lacks.

TypeDirect peer
Description

AI/ML platform for genetic medicine discovery. Comparable in applying AI to RNA biology and therapeutic target identification, with overlapping customer base in pharma R&D.

TypeEmerging player
Description

AI platform combining multi-omics and multimodal data for biomedical research. Comparable in applying AI to multi-omics data integration and predictive biology in pharma/biotech research settings.

TypeDirect peer
Description

Generative biology platform creating novel protein therapeutics using AI. Comparable in applying foundation-model-class architectures to programmable biology and therapeutic design.

9Isomorphic Labs
TypeDirect peer
Description

Alphabet/DeepMind-backed AI drug discovery company building foundation models for biology. Directly comparable to Astromech's stated mission of purpose-built AI architecture for biological reasoning, with substantially greater capital and compute resources.

TypeDirect peer
Description

AI foundation models for biology founded by former Meta AI researchers. Direct overlap with Astromech's Large Life Model concept and recently funded at unicorn-tier valuations, representing near-term competitive threat.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Astromech

Bioinformatics AI Platformastromech.com

Astromech, a Colossal Biosciences subsidiary, develops the Large Life Model — a proprietary AI system purpose-built to decode biological regulation and evolutionary logic across multi-species data for life sciences and biotech researchers.

What Astromech does

Astromech is a private AI company founded in 2025 and headquartered in Austin, Texas (Delaware-incorporated as Astromech AI Corp.), operating as a wholly-owned subsidiary of Colossal Biosciences. The company is building the "Large Life Model" — an autonomous biological intelligence system purpose-built to decode the regulatory and evolutionary logic of biology, in contrast to general-purpose large language models. The architecture is designed to operate across multi-species inputs and transcriptomic data, incorporating ancestral reconstruction to form a continuously updating biological intelligence layer that supports therapeutic development, trait optimization, programmable biology, and synthetic design. Target users are life sciences and biotech researchers working on understanding and shaping biological systems, with pain points centered on the lack of AI systems capable of multi-species analysis, ancestral reconstruction, and causal evolutionary reasoning.

The technical platform comprises five specialized components: the Pilot's Heuristic Processor (attention-based deep learner for multi-species transcriptomes), the Astrogation Buffer (Bayesian Ancestral Reconstruction for evolutionary trajectories), the Multi-socket Docking Bay (graph-based pangenome capturing population-scale structural variants), Tool-Appendage Calibration (Profile HMM alignment across divergent lineages), and the Droid Grid Network (multi-omics integrator in development). The system is described as an "AI Co-Pilot Through Evolutionary Frontiers" and is being designed to execute rather than merely assist. Leadership includes CEO Ben Lamm, Advisor George Church, and CLO Brian Beard, drawing on Colossal's de-extinction research programs (woolly mammoth, dire wolf, dodo, blue buck) as biological context.

Astromech operates in stealth with no publicly disclosed pricing, no commercial product storefront, and no named customer logos. Approximately $40 million has been raised through a 2025 $30M seed round and a March 2026 SEC Form D filing for $10,499,999, reaching a $2 billion+ unicorn valuation within nine months of founding. Go-to-market is relationship-driven, targeting research institutions and biotech companies through early-access newsletter signup and direct outreach, with an extensive job directory signaling aggressive technical talent acquisition.

Astromech firmographics

Firmographics
Name
Astromech
Legal name
Astromech AI Corp.
Website
https://astromech.com
Company type
Private
Founded year
2025
Operating status
Operating
Short description
Astromech, a Colossal Biosciences subsidiary, develops the Large Life Model — a proprietary AI system purpose-built to decode biological regulation and evolutionary logic across multi-species data for life sciences and biotech researchers.
Ownership category
akta.pro rank

Astromech industry classification

Industry
Product category
Bioinformatics AI Platform
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Biological AI systems
  • Genomic AI platform
  • Synthetic biology tools
  • Multi-omics analysis
  • Evolutionary reconstruction AI

Where Astromech is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Astromech business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations

Distribution channels1 record

Marketing channels2 records

Astromech product offering

Product offering

Core offering

Astromech develops an AI platform called the Large Life Model, purpose-built to decode the regulatory and evolutionary logic of biology. The system operates across multi-species inputs and transcriptomic data, incorporating ancestral reconstruction to form a continuously updating biological intelligence layer. It supports therapeutic development, trait optimization, programmable biology, genomic reasoning, synthesis design, and evolutionary reconstruction for life sciences and biotech research organizations.

Product overview

Astromech is an AI company founded as a subsidiary of Colossal Biosciences, developing a unified biological intelligence platform centered on the Large Life Model. This core AI system is complemented by five specialized technical components: the Pilot's Heuristic Processor (attention-based deep learning across transcriptomes), Astrogation Buffer (Bayesian ancestral reconstruction), Multi-socket Docking Bay (graph-based pangenome analysis), Tool-Appendage Calibration (Profile HMM alignment), and the Droid Grid Network (multi-omics integration). The platform is designed as an autonomous biological intelligence system that enables researchers to navigate, analyze, and predict biological processes at scale.

Differentiator

Problem solved

Functional benefit

Brands

  • Large Life Model: A developing AI system purpose-built to decode the regulatory and evolutionary logic of biology. It operates across multi-species inputs and transcriptomic data, incorporating ancestral reconstruction to form a continuously updating biological intelligence layer.

Products and services

  • Large Life Model An AI system purpose-built to decode the regulatory and evolutionary logic of biology. Operates across multi-species inputs and transcriptomic data with ancestral reconstruction capabilities, enabling high-resolution insights for therapeutic development, trait optimization, and programmable biology. Targeted at life sciences researchers and biotech organizations.

Companies that use Astromech

Customer profile

Segments1 record

Ideal customer profiles1 record

Astromech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Astromech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Colossal BiosciencescoreStrategic or Co-development PartnerAstromech was launched as an AI-focused subsidiary of Colossal Biosciences, a Texas-based biotech company founded by Ben Lamm. Colossal's work on de-extinction (woolly mammoth, dire wolf, dodo, Blue Buck) provides the biological research context for Astromech's Large Life Model development. The companies share founding leadership including Ben Lamm as CEO and George Church as Advisor.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Astromech competitors and assessment

Company assessment

Direct peers

  • Insitro: AI-driven drug discovery platform combining machine learning with high-throughput biology. Comparable in target customer (pharma/biotech research) and value proposition (predictive biology from large-scale data).
  • Cradle Bio: AI platform for protein engineering and design, serving biotech customers with generative biology tooling. Comparable in horizontal life-science R&D application and AI-driven design value proposition.
  • Recursion Pharmaceuticals: Publicly traded AI drug discovery company using high-dimensional biology and foundation models. Direct competitor in the AI-for-therapeutic-development category, with a mature pipeline and pharma partnerships Astromech lacks.
  • Deep Genomics: AI/ML platform for genetic medicine discovery. Comparable in applying AI to RNA biology and therapeutic target identification, with overlapping customer base in pharma R&D.
  • Generate Biomedicines: Generative biology platform creating novel protein therapeutics using AI. Comparable in applying foundation-model-class architectures to programmable biology and therapeutic design.
  • Isomorphic Labs: Alphabet/DeepMind-backed AI drug discovery company building foundation models for biology. Directly comparable to Astromech's stated mission of purpose-built AI architecture for biological reasoning, with substantially greater capital and compute resources.
  • EvolutionaryScale: AI foundation models for biology founded by former Meta AI researchers. Direct overlap with Astromech's Large Life Model concept and recently funded at unicorn-tier valuations, representing near-term competitive threat.

Broad incumbents

  • Benchling: Cloud-based R&D platform for life sciences (LIMS/ELN) used across pharma and biotech. Comparable as adjacent life-science informatics infrastructure serving similar research customers.
  • Ginkgo Bioworks: Large, publicly traded synthetic biology platform serving ag, industrial, and pharma customers. Comparable in synthetic biology positioning and horizontal life-science platform scope, though much broader and less AI-native.

Emerging players

  • Owkin: AI platform combining multi-omics and multimodal data for biomedical research. Comparable in applying AI to multi-omics data integration and predictive biology in pharma/biotech research settings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Astromech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Astromech leadership team

Management profile

Number of profiles

Profiles3 records

Astromech funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Astromech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astromech

What does Astromech do?

Astromech develops an AI platform called the Large Life Model, purpose-built to decode the regulatory and evolutionary logic of biology. The system operates across multi-species inputs and transcriptomic data, incorporating ancestral reconstruction to form a continuously updating biological intelligence layer. It supports therapeutic development, trait optimization, programmable biology, genomic reasoning, synthesis design, and evolutionary reconstruction for life sciences and biotech research organizations.

Is Astromech a public or private company?

Astromech is a private company. It is classified as corporate owned and is currently operating.

When was Astromech founded?

Astromech was founded in 2025.

Where is Astromech based?

Astromech is headquartered in Austin, United States, in the North America region.

Who are Astromech's main competitors?

Direct peers on record are Insitro, Cradle Bio, Recursion Pharmaceuticals, Deep Genomics, Generate Biomedicines, Isomorphic Labs and EvolutionaryScale. Broad incumbents are Benchling and Ginkgo Bioworks. Owkin is listed as an emerging player.

Does Astromech have an API?

No public API is recorded for Astromech.

What industry is Astromech in?

Astromech's product category is Bioinformatics AI Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Astromech Acquires Form Bio In $230 Million All-Stock DealAstromech acquired Form Bio in an all-stock deal valued at $230 million, combining evolutionary modeling with genetic medicine design software. Form Bio's co-founder Andrew Busey became Astromech's chief AI officer. The combined company plans to pursue applications in human therapeutics, genome engineering, and animal health.Dallas InnovatesAstromech Acquires Form Bio in $230M All-Stock DealAstromech acquired Form Bio in an all-stock deal valued at $230 million, bringing together two Dallas companies. Form Bio co-founder Andrew Busey became chief AI officer, and the combined company now employs 65 people. The acquisition is Astromech's first, aiming to integrate genetic medicine design tools.Third NewsAstromech's Strategic Acquisition of Form Bio: A Leap Into AI-Driven Genetic MedicineAstromech acquired Form Bio for $230 million to combine AI-driven genetic medicine with evolutionary insights. The deal aims to improve therapeutic design, with Form Bio's platform already boosting genome design efficiency from 13% to 59% in a Duchenne muscular dystrophy project. Both companies operate under the Colossal Biosciences ecosystem.Dealroom.coAstromech buys Form Bio in $230M all-stock deal for gene-medicine tools | Dealroom NewsAstromech acquired computational biology firm Form Bio in an all-stock deal valued at $230 million. The deal combines Astromech's predictive biological models with Form Bio's gene-medicine design tools, which have raised over $40 million. The companies, both spun out of Colossal Biosciences, aim to integrate their technologies to improve genomic quality at the design stage.PR NewswireAstromech Acquires Form Bio, Bringing Together Evolutionary AI and Genetic Medicine Design Under One DirectiveAstromech acquired Form Bio, combining evolutionary AI with genetic medicine design tools. Form Bio's AI-driven platform has helped Cure Rare Disease increase full-genome content from 13% to 59% in under 30 days. Both companies are part of the Colossal Biosciences ecosystem.Quasa is a metaverse that unites peopleAstromech Raises $20M at a Reported $3.8B ValuationAstromech raised $20 million at a $3.8 billion valuation, led by Bob Nelsen, with total capital now $60 million. The Dallas startup plans to expand its research team and scale infrastructure for its functional-genomics platform. The financing is established, but the company's ability to accurately predict biological change remains unproven.The SaaS NewsAstromech Raises $20M at $3.8B ValuationAstromech, a Dallas-based computational biology and AI startup, raised $20 million in funding on August 21, 2026, at a $3.8 billion valuation, bringing total capital to $60 million. The round was led by Bob Nelsen of ARCH Venture Partners, with participation from NeoGenesis Capital, Builders VC and a syndicate of genomics-focused funds. Funds will expand research teams, acquire multi-species genomic datasets and build computing infrastructure.TimeThe Woolly Mammoth’s Comeback Is Taking Longer Than ExpectedColossal Biosciences, the Dallas-based de-extinction firm, told TIME that its woolly mammoth project will move into the early 2030s, shifting from a 2028 birth target. The number of genes to edit rose from about 60 to roughly 150, and the company is developing woolly mice and a woolly pig. It also launched Astromech, an AI tool analyzing genomic data, including elephant cancer resistance.citybizAstromech $20M Funding Boosts Rise of Prediction-Focused AI in Life SciencesAstromech, an Austin-based AI company co-founded by Ben Lamm and George Church, has raised $20 million in fresh funding, bringing its total capital to $60 million and nearly doubling its valuation to $3.8 billion. The company is developing predictive AI models to analyze genetic data for applications such as forecasting drug resistance and identifying species at risk. This investment highlights continued investor interest in life sciences AI tools capable of accelerating drug discovery and improving conservation efforts.ForbesThis Billionaire Is Using AI To Forecast Evolutionary ChangeAstromech, a spinoff of de-extinction company Colossal, announced the closing of a $20 million venture funding round led by Arch Ventures, bringing its total valuation to $3.8 billion. The startup aims to utilize biological datasets collected during extinction research to build AI models that predict evolutionary changes in whole biological systems. This new capital will primarily be used for hiring research teams focused on mapping genes associated with longevity and disease resistance.